These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Protection of corneal allografts by CTLA4-Ig. Gebhardt BM; Hodkin M; Varnell ED; Kaufman HE Cornea; 1999 May; 18(3):314-20. PubMed ID: 10336035 [TBL] [Abstract][Full Text] [Related]
3. [Immunomodulation after keratoplasty by CTL4-Ig and anti-CD154 antibodies]. Zhang EP; Bulfone-Paus S; Hoffmann F Ophthalmologe; 2002 Mar; 99(3):183-7. PubMed ID: 11917801 [TBL] [Abstract][Full Text] [Related]
4. Effect of administration of CTLA4-Ig as protein or cDNA on corneal allograft survival. Comer RM; King WJ; Ardjomand N; Theoharis S; George AJ; Larkin DF Invest Ophthalmol Vis Sci; 2002 Apr; 43(4):1095-103. PubMed ID: 11923251 [TBL] [Abstract][Full Text] [Related]
5. CTLA4-Ig plus bone marrow induces long-term allograft survival and donor specific unresponsiveness in the murine model. Evidence for hematopoietic chimerism. Pearson TC; Alexander DZ; Hendrix R; Elwood ET; Linsley PS; Winn KJ; Larsen CP Transplantation; 1996 Apr; 61(7):997-1004. PubMed ID: 8623206 [TBL] [Abstract][Full Text] [Related]
6. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Kirk AD; Harlan DM; Armstrong NN; Davis TA; Dong Y; Gray GS; Hong X; Thomas D; Fechner JH; Knechtle SJ Proc Natl Acad Sci U S A; 1997 Aug; 94(16):8789-94. PubMed ID: 9238056 [TBL] [Abstract][Full Text] [Related]
7. Role of STAT4 and STAT6 signaling in allograft rejection and CTLA4-Ig-mediated tolerance. Zhou P; Szot GL; Guo Z; Kim O; He G; Wang J; Grusby MJ; Newell KA; Thistlethwaite JR; Bluestone JA; Alegre ML J Immunol; 2000 Nov; 165(10):5580-7. PubMed ID: 11067913 [TBL] [Abstract][Full Text] [Related]
8. Blockade of the B7-CD28 pathway by CTLA4-Ig counteracts rejection and prolongs survival in small bowel transplantation. Kurlberg G; Haglind E; Schön K; Törnqvist H; Lycke N Scand J Immunol; 2000 Mar; 51(3):224-30. PubMed ID: 10736090 [TBL] [Abstract][Full Text] [Related]
9. Modulation of costimulation by CD28 and CD154 alters the kinetics and cellular characteristics of corneal allograft rejection. Ardjomand N; McAlister JC; Rogers NJ; Tan PH; George AJ; Larkin DF Invest Ophthalmol Vis Sci; 2003 Sep; 44(9):3899-905. PubMed ID: 12939307 [TBL] [Abstract][Full Text] [Related]
10. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28. Lin H; Rathmell JC; Gray GS; Thompson CB; Leiden JM; Alegre ML J Exp Med; 1998 Jul; 188(1):199-204. PubMed ID: 9653096 [TBL] [Abstract][Full Text] [Related]
12. Prolongation of corneal allograft survival by CTLA4-FasL in a murine model. Shi W; Chen M; Xie L Graefes Arch Clin Exp Ophthalmol; 2007 Nov; 245(11):1691-7. PubMed ID: 17541621 [TBL] [Abstract][Full Text] [Related]
14. [CTLA4-Ig prevents corneal allograft rejection in mice]. Shi WY; Xie LX Zhonghua Yan Ke Za Zhi; 2004 Oct; 40(10):696-700. PubMed ID: 16200862 [TBL] [Abstract][Full Text] [Related]
15. Preventing allograft rejection with CTLA4IG: effect of donor-specific transfusion route or timing. Bolling SF; Lin H; Wei RQ; Turka LA J Heart Lung Transplant; 1996 Sep; 15(9):928-35. PubMed ID: 8889989 [TBL] [Abstract][Full Text] [Related]
16. CTLA4-Ig inhibits rejection of mouse liver allografts from Flt3-ligand-treated donors and is associated with increased lymphocyte apoptosis. Li W; Lu L; Wang Z; Wang L; Thomson A; Fung J; Qian S Transplant Proc; 2001; 33(1-2):246-7. PubMed ID: 11266801 [No Abstract] [Full Text] [Related]
17. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blazar BR; Taylor PA; Linsley PS; Vallera DA Blood; 1994 Jun; 83(12):3815-25. PubMed ID: 7515723 [TBL] [Abstract][Full Text] [Related]